Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment.

Madhumitha HaridossAkhil SasidharanSajith KumarKavitha RajsekarKrishnamurthy VenkataramanBhavani Shankara Bagepally

Published in: Applied health economics and health policy (2024)

TNF-α, B cell, and JAK-inhibitors are not cost-effective compared with csDMARDs for patients with RA who have not responded to MTX in India at the current prices. Cost-effectiveness estimates were highly influenced by drug pricing variations. Therefore, reducing the prices of these interventions could enhance affordability, potentially leading to their inclusion in publicly funded health programs.

Keyphrases

rheumatoid arthritis
public health
disease activity
healthcare
mental health
emergency department
ankylosing spondylitis
systemic lupus erythematosus
risk assessment
social media
combination therapy
smoking cessation